Investors seeking to outperform the market often focus on hand-picking stocks. Selecting the right ones has proven to be a key factor in boosting wealth.
Outlook Therapeutics Inc (NASDAQ: OTLK) closed the day trading at $0.96 down -2.73% from the previous closing price of $0.99. In other words, the price has decreased by -$2.73 from its previous closing price. On the day, 1.44 million shares were traded. OTLK stock price reached its highest trading level at $1.02 during the session, while it also had its lowest trading level at $0.96.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Sep 26 ’24 when KENYON LAWRENCE A bought 5,000 shares for $5.69 per share. The transaction valued at 28,446 led to the insider holds 5,946 shares of the business.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, OTLK now has a Market Capitalization of 42776004 and an Enterprise Value of 68572896. For the stock, the TTM Price-to-Sale (P/S) ratio is 28.33. Its current Enterprise Value per Revenue stands at 45.554 whereas that against EBITDA is -0.946.
Stock Price History:
The Beta on a monthly basis for OTLK is 0.55, which has changed by -0.82741934 over the last 52 weeks, in comparison to a change of 0.1653893 over the same period for the S&P500. Over the past 52 weeks, OTLK has reached a high of $6.98, while it has fallen to a 52-week low of $0.79. The 50-Day Moving Average of the stock is -47.01%, while the 200-Day Moving Average is calculated to be -43.60%.
Shares Statistics:
Over the past 3-months, OTLK traded about 3.37M shares per day on average, while over the past 10 days, OTLK traded about 2657850 shares per day. A total of 43.48M shares are outstanding, with a floating share count of 29.09M. Insiders hold about 34.52% of the company’s shares, while institutions hold 20.57% stake in the company. Shares short for OTLK as of 1756425600 were 6807948 with a Short Ratio of 2.02, compared to 1753920000 on 2349479. Therefore, it implies a Short% of Shares Outstanding of 6807948 and a Short% of Float of 18.620001.
Earnings Estimates
Outlook Therapeutics Inc (OTLK) is presently subject to a detailed evaluation by 3.0 analysts, each offering their unique perspectives on its market standing.The consensus estimate for the next quarter is -$0.25, with high estimates of -$0.09 and low estimates of -$0.42.
Analysts are recommending an EPS of between -$1.72 and -$1.89 for the fiscal current year, implying an average EPS of -$1.81. EPS for the following year is -$1.17, with 3.0 analysts recommending between -$0.28 and -$1.67.
Revenue Estimates
For the next quarter, 3 analysts are estimating revenue of $4.4M. There is a high estimate of $5M for the next quarter, whereas the lowest estimate is $3.8M.
Based on 5 analysts’ estimates, the company’s revenue will be $27.8M in the next fiscal year. The high estimate is $51M and the low estimate is $15.92M.
